Daniel Jenkin
Daneil Jenkin
MBChB, MSc, DTM&H, MRCP
CLINICAL RESEARCH FELLOW
Recent publications
-
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial
Journal article
Satti I. et al, (2024), The Lancet Infectious Diseases
-
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Journal article
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964
-
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Journal article
Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287
-
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Journal article
Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
-
Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial
Journal article
Jenkin D. et al, (2022), The Lancet Microbe, 3, e663 - e671